FNCH Company Profile and Key Details

Q: Who are the executives of FNCH?

Dr. Alka Batycky Ph.D.Chief Devel. OfficerMr. James S. SiglerExecutive Vice President of CMCDr. Howard Franklin M.B.A., M.D.Chief Medical OfficerMr. Matthew P. BlischakChief Executive OfficerMr. Lance Thibault C.P.A., CPAChief Financial OfficerDr. Mark Burnham Smith Ph.D.Chief Executive Officer & DirectorMr. Marc B. Blaustein C.F.A., CFA, MPPChief Operating Officer and Principal Financial & Accounting OfficerMs. Sonia TimberlakeSenior Vice President of ResearchMr. Bryan Gillis M.B.A.Chief Technology OfficerMatt Nelson M.B.A.Vice President of Fin.Dr. Howard J. Franklin M.B.A., M.D.Senior Vice President of MedicalMr. Matthew P. Blischak J.D.Chief Executive OfficerMr. Lance Thibault CPA, CPAActing Vice President of Fin.Mr. James S. Sigler MBAExecutive Vice President of CMC

NASDAQ : FNCH

Finch Therapeutics Group

$13.20

-0.05-0.38%

At Close 4:00 PM

63.43

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Finch Therapeutics Group, Inc. (FNCH) stock remained unchanged at $13.25 a share on OTC. The stock opened at $13.50, fluctuating between $13.20 to $13.50 during the session.

Stock Snapshot

13.25

Prev. Close

21.28M

Market Cap

13.2

Day Low

-1.51

P/E Ratio

-8.8

EPS (TTM)

-19.62

Cash Flow per Share

13.5

Open

1.61M

Number of Shares

13.5

Day High

55.81%

Free Float in %

14.25

Book Value

1.09K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 25, 2026	13.50	13.50	13.20	13.20	3.26K
Feb 24, 2026	12.94	13.10	12.94	13.10	573
Feb 23, 2026	12.89	12.89	12.89	12.89	157
Feb 20, 2026	12.75	12.80	12.75	12.80	1.16K
Feb 19, 2026	13.00	13.00	12.80	13.00	2.68K
Feb 18, 2026	13.01	13.01	13.01	13.01	136
Feb 17, 2026	13.13	13.13	12.75	12.75	3.08K
Feb 13, 2026	13.32	13.49	13.25	13.30	1.95K
Feb 12, 2026	13.25	13.33	13.25	13.25	875
Feb 09, 2026	13.70	13.75	13.70	13.75	4.82K
Feb 06, 2026	13.33	13.70	12.70	13.70	2.2K
Feb 05, 2026	13.70	13.70	13.55	13.70	1.05K
Feb 04, 2026	13.74	13.74	13.74	13.74	205
Feb 02, 2026	13.74	13.74	13.74	13.74	103
Jan 30, 2026	13.74	13.74	13.51	13.51	6
Jan 29, 2026	13.74	13.74	13.74	13.74	147
Jan 28, 2026	13.75	13.80	13.70	13.75	792
Jan 27, 2026	14.08	14.08	13.51	13.75	16.4K
Jan 26, 2026	14.08	14.25	14.08	14.08	1.22K
Jan 23, 2026	14.15	14.29	14.15	14.29	602

Contact Details

Somerville, MA 02143

United States

https://www.finchtherapeutics.com 617 229 6499

About Company

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.

Stock Peers

ODTC

Odonate Therapeutics, Inc.$2,849.50 GNMSF

Genmab A/S$268.61 CMXHF

CSL Limited$192.00 NONOF

Novo Nordisk A/S$144.95 CSLLY

0.75+0.79%

CSL Limited$95.35 UCBJY

-0.06-0.08%

UCB SA$73.15 PHMMF

4.3+16.01%

Pharma Mar, S.A.$31.15 BVNKF

Bavarian Nordic A/S$21.20 NURPF

Neuren Pharmaceuticals Limited$14.00 TLPPF

Telix Pharmaceuticals Limited$11.00

Company Overview

The stock is currently mid-range between its 52-week high and low $11.50 and $16.10. With a market capitalization of about $21.28 million, Finch Therapeutics Group, Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.16). Key stats such as the average daily volume over the past year has been around 1.81 thousand shares, volume is running light vs its 52-week average. Headquartered in Somerville, MA, Finch Therapeutics Group, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Matthew Blischak, the company employs approximately 1 people and listed since March 19, 2021. Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States.

Technical Performance

FNCH has shown weak momentum, losing -45.98% over the past week and -52.36% over the past quarter, though year-to-date performance is down -66.48%. Short-term trend indicators are bullishly aligned (SMA20 -49.83%, SMA50 -56.73%, SMA200 -72.98%). The stock’s 14-day RSI is 29.56 (weak momentum), while the ATR of 0.35 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -94.21% below its high and over 21.25% above its low. Average 10-day trading volume of 1.33 thousand shares is below the 3-month average of 2.92 thousand, indicating normal recent market interest.

Valuation Metrics

Finch Therapeutics Group, Inc. trades at a P/E ratio of -1.53, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.33 suggesting the stock is closer to book value. The P/FCF stands at -0.67, also below market averages.

Dividend & Fair Value

Finch Therapeutics Group, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$10.92. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Finch Therapeutics Group, Inc. generated EPS of -$10.14 over the past year. Five-year average earnings growth is -37.86%. Wall Street analysts project EPS growth of 41.7% annually over the next five years. Finch Therapeutics Group, Inc. earnings surprise history is a mixed track record. The quarter that ended November 09, 2023, missed forecasts by -73.37%. The prior quarter beat by -3.99%. Over the last six quarters, Apple has recorded several small beats. These include 4.34% in August 11, 2022.

Shareholding & Insider Activity

Finch Therapeutics Group, Inc. has 1.61 million shares outstanding. The public float is 896.19 thousand shares, elevated short interest at 2.76% of float. This equals 19.20 thousand shares. The short ratio is 0.19 days. Institutional investors hold 0.54% of the float. Insiders own 13.39%. Crestovo Investor LLC holds 12.64 million shares, Haft Nicholas has 4.06 million shares and FERRANTE DOMENIC J has 636.20 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, Finch Therapeutics Group generated $107.00K in revenue, or $0.07 per share. Gross margin was -1320.56%, operating margin -31777.57%, and net profit margin -69863.55%. Returns are negative, with ROA at -105.29% and ROE at -326.64%.
On valuation metrics, Finch Therapeutics Group trades at a P/E of -1.53, P/S of 0.00 and P/B of 2.33. The current ratio is 3.39 and quick ratio is 3.39. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -310.46 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 3.06, supported by a cash flow-to-debt ratio of -1.13.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Finch Therapeutics Group posted revenue of $107.00K, down slightly from $861.00K in the prior quarter. Gross profit was - $1.41M (margin -1320.56%). Operating income was - $34.00M (margin -31777.6%). Net income was- $74.75M (EPS - $46.59).
The company ended the quarter with $25.12M in cash and short-term investments, a total debt of $30.13M, and net debt of $5.00M. Total assets were $71.00M, with equity of $22.89M. Financials further reflected weakness, with operating cash flow of - $31.51M, free cash flow of - $31.51M, and capital expenditures of $0.00.

Price Forecast & Outlook

Our AI price prediction model suggests that Finch Therapeutics Group, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -4.7%, with price expected at $12.58 by March 11, 2026, within a range of $12.34 to $12.84 3-Month Outlook: Projected fall of -18.41%, reaching $10.77 by May 26, 2026, with a range of $10.30 to $11.16. 1-Year Outlook: Projected gain of 92.05%, with price at $25.35 by February 25, 2027, within a range of $10.36 to $35.50.

Key Takeaways

Finch Therapeutics Group, Inc. (NASDAQ:FNCH) shares are down -66.48% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Finch Therapeutics Group, Inc. trading at a premium to the broader market with a P/E of -1.53. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $17.67, suggesting 33.86% upside. Our AI forecast model points to short-term weakness (-4.7% over two weeks), a medium-term fall (-18.41% over three months), and a longer-term gain (92.05% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Finch Therapeutics Group, Inc. (FNCH) stock price?

Finch Therapeutics Group, Inc. (OTC: FNCH) stock price is $13.25 in the last trading session. During the trading session, FNCH stock reached the peak price of $13.50 while $13.20 was the lowest point it dropped to. The percentage change in FNCH stock occurred in the recent session was 0% while the dollar amount for the price change in FNCH stock was $0.00.

FNCH's industry and sector of operation?

The OTC listed FNCH is part of Biotechnology industry that operates in the broader Healthcare sector. Finch Therapeutics Group, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of FNCH?

Dr. Alka Batycky Ph.D.
Chief Devel. Officer
Mr. James S. Sigler
Executive Vice President of CMC
Dr. Howard Franklin M.B.A., M.D.
Chief Medical Officer
Mr. Matthew P. Blischak
Chief Executive Officer
Mr. Lance Thibault C.P.A., CPA
Chief Financial Officer
Dr. Mark Burnham Smith Ph.D.
Chief Executive Officer & Director
Mr. Marc B. Blaustein C.F.A., CFA, MPP
Chief Operating Officer and Principal Financial & Accounting Officer
Ms. Sonia Timberlake
Senior Vice President of Research
Mr. Bryan Gillis M.B.A.
Chief Technology Officer
Matt Nelson M.B.A.
Vice President of Fin.
Dr. Howard J. Franklin M.B.A., M.D.
Senior Vice President of Medical
Mr. Matthew P. Blischak J.D.
Chief Executive Officer
Mr. Lance Thibault CPA, CPA
Acting Vice President of Fin.
Mr. James S. Sigler MBA
Executive Vice President of CMC

How FNCH did perform over past 52-week?

FNCH's closing price is 14.78% higher than its 52-week low of $11.50 where as its distance from 52-week high of $16.10 is -18.01%.

How many employees does FNCH have?

Number of FNCH employees currently stands at 1.

Link for FNCH official website?

Official Website of FNCH is: https://www.finchtherapeutics.com

How do I contact FNCH?

FNCH could be contacted at phone 617 229 6499 and can also be accessed through its website. FNCH operates from 200 Inner Belt Road, Somerville, MA 02143, United States.

How many shares of FNCH are traded daily?

FNCH stock volume for the day was 1.09K shares. The average number of FNCH shares traded daily for last 3 months was 1.81K.

What is the market cap of FNCH currently?

The market value of FNCH currently stands at $21.28M with its latest stock price at $13.25 and 1.61M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	1
Beta	1.16
Sales or Revenue	$107.00K
5Y Sales Change%	-0.989%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

FNCH Company Profile and Key Details

Finch Therapeutics Group

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Company Overview

Valuation Metrics

Price Forecast & Outlook

Key Takeaways